MONTHLY DOSE

MARCH 2019

MONTHLY DOSE

MAY 2021

Biocon Biologics provided 7,000 doses of Itolizumab in April

Glenmark Pharma launches nasal spray Ryaltris in India

Pfizer donates USD70mn worth Covid-19 treatment drugs to India

Aleor Dermaceuticals receives USFDA tentative approval for Metronidazole Gel USP, 1%

Serum Institute to invest 240 million pounds in UK; leads cross-sector Indian investments

Cadila extends tenure of joint venture with Bayer Pte

Alembic Pharmaceuticals announces USFDA final approval for Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution

Hikal signs a 10-year multi product deal with a leading global pharmaceutical innovator company

Covid drug: Natco eyes patent waiver

Roche India gets emergency use approval for antibody cocktail used in Covid-19 treatment

J B Chemicals forays into nephrology segment in India

Ajanta Pharma earmarks Rs250cr capex for current fiscal

Cipla, Lupin, Sun Pharma to make, sell low-cost versions of Lilly's Covid-19 drug

Vivimed Labs gets DGHS nod to manufacture, market Favipiravir tablets in India

Bharat Biotech commences direct supply of 'Covaxin' to 14 states

Zydus Cadila prices Covid-19 medicine Virafin at Rs11,995 per dose

Zydus Animal Health and Investment Ltd entered into a business transfer agreement for disposal of its Animal Healthcare Established Markets

Dr. Reddy announces the launch of Ertapenem for injection in the US market

Hester in talks with Bharat Biotech for production of Covaxin via technology transfer

Shilpa Medicare Limited ties up with Dr. Reddy's for production of Sputnik V vaccine

Panacea Biotec files suit against Sanofi for patent infringement

Dr. Reddy's in talks with RDIF on Sputnik V for other countries

Gland Pharma buys Vitane’s assets to scale up production of Sputnik V

Cipla launches RT-PCR test kit 'ViraGen' in India partnership with Ubio Biotech

Gufic Biosciences gets nod to manufacture and market Liposomal Amphotericin B Injection

Natco starts Phase-III clinical trial of Molnupiravir capsules for Covid-19 treatment

Roche’s antibody cocktail (Casirivimab and Imdevimab) is now available in India, Cipla to market it pan-India

Zydus launches Ujvira (Trastuzumab Emtansine), a breakthrough in breast cancer treatment

India reaches out to US companies over investment in pharmaceutical, medical devices sector

Covid second wave pushes India's pharma industry growth to 59% in April

Pharma industry seeks 20% hike in drug prices citing rising input costs

Pharma Industry to be given priority to come back to operation post taukate: Goyal

US approves Pfizer Covid-19 vaccine for children aged 12 to 15

Sanofi, GSK’s Covid-19 vaccine achieves positive Phase II results

Industry

Company

Global

News for the Month

Source: Media Reports and Company Press Releases

Company API Strengths Indications Brand (Company) Mkt Size

Alembic Pharma

Dorzolamide Hydrochloride. and

Timolol Maleate Ophthalmic Solution

2% and 0.5% Indicated for the reduction of elevatedintraocular pressure (IOP)

in patients with open-angle glaucoma

Cosopt Ophthalmic Solution (Akorn

Operating Company LLC.)

USD80mn

Alembic Pharma

Lurasidone Hydrochloride

Tablets

20/40/60/80/120mg Indicated for monotherapy treatment of adult and pediatric patients

Latuda Tablets (Sunovion Pharmaceuticals Inc.)

USD3.7bn

Natco Everolimus Tablets 0.25/0.5/0.75mg Indicated in the prophylaxis of organ rejection in kidney transplantation and liver

transplantation

ZORTRESS USD162mn (annual sales)

Natco Lenalidomide Capsules

5/10/15/25mg Used to treat various types of cancers

REVLIMID (Celgene Corporation)

USD10bn (2019 annual sales)

Glenmark Icatibant Injection 30 mg/3mL (10 mg/mL)

Single-Dose Prefilled Syringe

Used to treat attacks of hereditary angioedema

Firazy (Shire Human Genetic Therapies, Inc.)

USD223.4mn (annual sales)

Cadila Fluphenazine Hydrochloride

Tablets

1/2.5/5/10mg Used to treat symptoms of a certain type of mental/mood condition

(schizophrenia)

Prolixin Tablets USD134mn (December 2020

sales)

Source: Media Reports and Company Press Releases

Final ANDA Approvals:

Tentative ANDA Approvals:

Company API Strengths Indications Brand (Company) Mkt Size

Alembic Pharma

Metronidazole Gel

1% Indicated for the topical treatment of inflammatory lesions of rosacea

Metrogel Gel (Galderma Laboratories LP)

USD32mn

Natco Lenalidomide Capsules

2.5/20mg Used to treat various types of cancers

REVLIMID (Celgene Corporation)

USD10bn (2019 annual sales)

Source: Media Reports and Company Press Releases

BSE Health Care Index Price Performance

Companies

Price

Change

1 M 6 M 12 M

Aarti Drugs Ltd 727 2.5% 3.2% -23.7%

Abbott India Ltd 16010 5.7% 4.0% -4.8%

Ajanta Pharma Ltd 1921 4.3% 25.3% 32.5%

Alembic Ltd 129 16.9% 22.1% 138.8%

Alembic Pharmaceuticals Ltd 951 -3.5% -3.5% 11.8%

Alkem Laboratories Ltd 2985 8.3% 7.0% 30.8%

Apollo Hospitals Enterprise Ltd 3170 -0.9% 28.8% 130.9%

AstraZeneca Pharma India 3774 -3.4% -16.7% 22.1%

Aurobindo Pharma Ltd 998 1.7% 11.2% 37.5%

Biocon Ltd 388 2.1% -10.5% 0.5%

Bliss GVS Pharma Ltd 108 6.0% -36.7% 13.9%

Cadila Healthcare Ltd 618 8.2% 36.4% 76.9%

Caplin Point Laboratories Ltd 597 20.8% 23.0% 82.8%

Cipla Ltd 949 4.2% 25.6% 47.8%

Divi's Laboratories Ltd 4194 3.2% 15.8% 69.0%

Dr. Reddy's Laboratories Ltd 5308 2.8% 9.9% 34.4%

Dr. Lal PathLabs Ltd 2956 0.8% 30.2% 94.3%

Eris Lifesciences Ltd 711 18.4% 36.9% 34.6%

FDC Ltd 341 12.1% -0.6% 33.4%

Fortis Healthcare Ltd 228 8.1% 48.9% 89.4%

GSK Pharmaceuticals Ltd 1516 4.3% -2.3% 10.5%

Glenmark Pharmaceuticals Ltd 593 2.8% 24.3% 60.8%

Granules India Ltd 318 -4.6% -25.7% 85.8%

Gufic Biosciences Ltd 182 33.1% 54.7% 226.1%

HealthCare Global Enterprises Ltd 183 3.3% 22.7% 62.5%

Hester Biosciences Ltd 2744 23.1% 53.4% 137.8%

Hikal Ltd 394 48.4% 129.9% 240.4%

Indoco Remedies Ltd 393 19.6% 46.6% 88.7%

Indraprastha Medical Corp. Ltd 87 29.7% 66.7% 109.2%

IOL Chemicals and Pharma Ltd 701 18.4% -10.7% 85.6%

IPCA Laboratories Ltd 2071 -1.7% -9.0% 35.7%

J.B. Chemicals & Pharma Ltd 1452 4.1% 44.2% 111.2%

Jubilant Life Sciences Ltd 872 9.2% 20.0% 87.7%

Kopran Ltd 187 10.6% 45.4% 588.6%

BSE Health Care Index Price Performance

Companies

Price

Change

1 M 6 M 12 M

Laurus Labs Ltd 523 15.4% 62.1% 462.5%

Lincoln Pharmaceuticals Ltd 293 3.9% 23.2% 88.6%

Lupin Ltd 1219 14.0% 34.0% 43.6%

Mangalam Drugs and Organics Ltd 130 -8.0% -11.9% 135.8%

Marksans Pharma Ltd 74 3.4% 20.8% 208.8%

Medicamen Biotech Ltd 553 11.6% 38.3% 137.0%

Merck Ltd 5911 -6.9% -11.0% 37.5%

Morepen Laboratories Ltd 55 -15.6% 90.0% 240.7%

Narayana Hrudayalaya Ltd 439 8.3% 14.9% 48.5%

Natco Pharma Ltd 1051 17.3% 15.0% 79.5%

Nectar Lifesciences Ltd 31 24.2% 68.8% 134.2%

Neuland Laboratories Ltd 2121 -15.9% 101.1% 442.1%

Novartis India Ltd 653 0.6% 1.8% 13.4%

Opto Circuits India Ltd 5 -9.6% -15.1% -35.8%

Panacea Biotec Ltd 410 23.2% 99.1% 174.1%

Pfizer Ltd (India) 5134 -2.6% 0.6% 27.9%

Piramal Enterprises Ltd 1815 8.1% 28.4% 63.0%

Poly Medicure Ltd 1018 2.3% 108.5% 228.3%

RPG Life Sciences Ltd 442 -8.2% 19.6% 69.3%

Sanofi India Ltd 7719 2.2% -3.4% -0.9%

Shalby Ltd 170 59.6% 54.7% 150.7%

Shilpa Medicare Ltd 517 21.1% 8.8% 30.9%

SMS Pharmaceuticals Ltd 167 10.8% 79.8% 311.5%

Strides Shasun Ltd 766 -11.4% -3.8% 91.7%

SPARC Ltd 224 28.2% 21.0% 62.9%

Sun Pharmaceutical Industries Ltd 668 2.1% 23.8% 43.7%

Suven Life Sciences Ltd 94 -8.6% 97.0% 172.7%

Syngene International Ltd 585 5.9% 2.9% 63.7%

Thyrocare Technologies Ltd 1065 4.0% -0.6% 102.9%

Torrent Pharmaceuticals Ltd 2740 9.2% 3.3% 17.8%

Unichem Laboratories Ltd 338 5.3% 30.0% 169.0%

Vimta Labs Ltd 223 -13.2% 57.0% 205.3%

Vivimed Labs Ltd 30 -12.9% 76.2% 188.5%

Wockhardt Ltd 650 26.2% 40.7% 201.0%

Source: BSE website; All prices are as on 31st May 2021

Source: BSE website; All prices are as on 31st May 2021

NIFTY PHARMA COMPANIES

Company

Price (Rs)

Mcap (Rsmn)

Change

1 M 6 M 12 M

Aurobindo Pharma Ltd. 998 584620 1.74% 11.2% 37.5%

Biocon Ltd. 388 465120 2.1% -10.5% 0.5%

Cadila Healthcare Ltd. 618 632980 8.2% 36.4% 76.9%

Cipla Ltd. 949 765455 4.2% 25.6% 47.8%

Divi's Laboratories Ltd. 4194 1113269 3.2% 15.8% 69.0%

Dr. Reddy's Laboratories Ltd. 5308 882727 2.8% 9.9% 34.4%

Glenmark Pharmaceuticals Ltd. 593 167213 2.8% 24.3% 60.8%

Lupin Ltd. 1219 553081 14.0% 34.00% 43.6%

Piramal Enterprises Ltd. 1815 409431 8.1% 28.4% 63.0%

Sun Pharmaceutical Industries Ltd. 668 1603476 2.1% 23.8% 43.7%

Source: NSE website, Company Research; All prices are as on 31st May 2021

Nifty Pharma Index Vs. Nifty Index

Source: NSE website

DISCLAIMERS AND DISCLOSURES- Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products. PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time. PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report-: · PSBPL or its associates financial interest in the subject company: NO · Research Analyst (s) or his/her relative's financial interest in the subject company: NO · PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company. · PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO · Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO · PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months. · The research Analyst has served as officer, director or employee of the subject company: NO PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read “Risk Disclosure Document for Capital Market and Derivatives Segments” as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. Terms & Conditions: This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Compliance Officer: Mr. Shyam Agrawal, Email Id: compliance@progressiveshares.com, Contact No.:022-40777500.

Registered Office Address: Progressive Share Brokers Pvt. Ltd, 122-124, Laxmi Plaza, Laxmi Indl Estate, New Link Rd, Andheri West, Mumbai-400053; www.progressiveshares.com Contact No.:022-40777500.